Pharvaris executive reports initial share holdings
Pharvaris N.V. executive Stefan Andreas Abele, Chief Technical Ops Officer, reports his initial equity holdings.
Rhea-AI Filing Summary
Pharvaris N.V. executive Stefan Andreas Abele, Chief Technical Ops Officer, reports his initial equity holdings. He holds several stock option awards over common shares, including options exercisable at $28.0000, $16.0500, $22.3100 and $16.4000, with expiration dates between November 15, 2033 and March 3, 2036. These options cover 60,000, 60,000, 40,000 and 89,500 underlying common shares, respectively. He also reports direct ownership of 43,942 shares of common stock as of March 18, 2026, which includes restricted stock units granted under the company’s equity plan that vest over time according to the schedules described in the footnotes.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (5)
- F1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -20,000 RSUs from an award granted March 3, 2026 of which 25% vested March 3, 2027 with the remainder vesting monthly thereafter; -15,000 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting monthly thereafter; -6,849 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting monthly thereafter.
- F2. 25% of the option will vest on March 3, 2027 with the remaining shares vesting in 1/48 monthly installments thereafter.
- F3. 25% of the option vested on March 12, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter.
- F4. 25% of the option vested on April 11, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter.
- F5. 25% of the option vested on November 15, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Pharvaris (PHVS) Form 3 for Stefan Andreas Abele report?
What direct common stock holdings does Stefan Andreas Abele report in Pharvaris (PHVS)?
How do Stefan Andreas Abele’s Pharvaris (PHVS) stock options vest?
What are the key details of Abele’s restricted stock units in Pharvaris (PHVS)?
AI-generated analysis. How Rhea-AI works. Not financial advice.